Fenwick & West represented BioAge Labs, Inc., a developer of a machine learning and systems biology platform to identify the key biological pathways and drug targets that impact human longevity, in its $23 million Series B financing. Felicis Ventures led the round with participation from existing investors Andreessen Horowitz, Caffeinated Capital, PEAR Ventures and AME Cloud Ventures, and new investors and partners Kholsa Ventures and Redpoint Ventures.
With the new financing, BioAge will scale its AI-driven platform to discover and develop drugs that treat aging. The company will also scale its efforts to advance drug targets in parallel. More information on BioAge’s $23 million Series B financing can be obtained from the company announcement.
The Fenwick transaction team was led by corporate lawyers Matt Rossiter, Nam Kim, Amy Zhang and Vincent Sheu.